

# 1 **Coupled structural transitions enable highly cooperative regulation of** 2 **human CTPS2 filaments**

3  
4 Eric M. Lynch<sup>1</sup> & Justin M. Kollman<sup>1\*</sup>

5 <sup>1</sup>Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA

6 \*Corresponding author

7  
8 **Many enzymes assemble into defined oligomers, providing a mechanism for**  
9 **cooperatively regulating enzyme activity. Recent studies in tissues, cells, and *in vitro***  
10 **have described a mode of regulation in which enzyme activity is modulated by**  
11 **polymerization into large-scale filaments<sup>1-5</sup>. Enzyme polymerization is often driven by**  
12 **binding to substrates, products, or allosteric regulators, and tunes enzyme activity by**  
13 **locking the enzyme in high or low activity states<sup>1-5</sup>. Here, we describe a unique,**  
14 **ultrasensitive form of polymerization-based regulation employed by human CTP**  
15 **synthase 2 (CTPS2). High-resolution cryoEM structures of active and inhibited CTPS2**  
16 **filaments reveal the molecular basis of this regulation. Rather than selectively stabilizing**  
17 **a single conformational state, CTPS2 filaments dynamically switch between active and**  
18 **inactive filament forms in response to changes in substrate and product levels. Linking**  
19 **the conformational state of many CTPS2 subunits in a filament results in highly**  
20 **cooperative regulation, greatly exceeding the limits of cooperativity for the CTPS2**  
21 **tetramer alone. The structures also reveal a link between conformational state and**  
22 **control of ammonia channeling between the enzyme's two active sites. This filament-**  
23 **based mechanism of enhanced cooperativity demonstrates how the widespread**  
24 **phenomenon of enzyme polymerization can be adapted to achieve different regulatory**  
25 **outcomes.**

26  
27 CTP synthase (CTPS) is the key regulatory enzyme in pyrimidine biosynthesis, with critical roles  
28 in regulation of nucleotide balance<sup>6</sup>, maintenance of genome integrity<sup>7,8</sup>, and synthesis of  
29 membrane phospholipids<sup>9</sup>. CTPS catalyzes the conversion of UTP to CTP in an ATP-dependent  
30 process, the rate-limiting step in CTP synthesis. CTPS is regulated through feedback inhibition  
31 by CTP binding, and is allosterically regulated by GTP, making it sensitive to levels of the four  
32 essential ribonucleotides, reflecting its role as a critical regulatory node in nucleotide  
33 metabolism<sup>10-13</sup>. CTPS is a homotetramer, with each monomer composed of a glutaminase and  
34 an amidoligase domain connected by a helical linker<sup>14</sup>. Ammonia is generated from glutamine  
35 then transferred to the amidoligase domain, where it is ligated to UTP to form CTP; while both of

36 these catalytic mechanisms are well understood, the mechanism of ammonia transfer between  
37 the two separated active sites has not yet been described. Previously, we showed that CTPS  
38 undergoes a conserved conformation cycle controlled by substrate and product binding,  
39 involving two major structural changes: upon substrate binding, the glutaminase domain rotates  
40 towards the amidoligase domain, bringing the two active sites closer, and the tetramer interface  
41 rearranges to accommodate UTP binding<sup>5</sup>.

42 Humans have two CTPS isoforms encoded on separate genes, CTPS1 and CTPS2, that  
43 share 75% identity. Their relative roles remain unclear. CTPS1 plays a specific and central role  
44 in lymphocyte proliferation, and its loss in humans causes severe immune deficiency<sup>15,16</sup>. CTPS  
45 is frequently misregulated in cancer<sup>7,17</sup>, with CTPS2 misregulation specifically implicated in  
46 osteosarcoma<sup>18</sup>. Given these roles in health and disease, how the two human enzymes are  
47 differentially regulated remains an open question of clinical significance.

48 Polymerization provides an additional layer of CTPS regulation, although the  
49 mechanisms by which filaments modulate enzyme activity vary among species. In *E. coli* CTPS  
50 filaments stabilize a product-bound, inactive conformation of the enzyme, leading to enhanced  
51 inhibition in the filament<sup>1,5</sup>. By contrast, human CTPS1 forms hyper-active filaments composed  
52 of enzyme in an active, substrate-bound conformation that disassemble on CTP binding<sup>5</sup>. CTPS  
53 filaments appear in response to cellular stress, during particular developmental stages, and in  
54 tumor tissue, suggesting a role in adaptation to changing metabolic needs<sup>19-23</sup>.

55

56

## 57 RESULTS

58

### 59 CTPS2 forms distinct substrate- and product-bound filaments

60 Given the importance of understanding the regulatory differences between the two human  
61 isoforms and the observed variation in filament-based regulation among species, we aimed to  
62 determine whether there are differences in filament structure and function between CTPS1 and  
63 CTPS2. We imaged CTPS2 by negative stain EM in the presence of substrates UTP and ATP  
64 or products CTP and ADP (Fig. 1a). Surprisingly, unlike CTPS1, which only assembles in the  
65 substrate-bound conformation and disassembles upon CTP addition, either substrates or  
66 products promoted CTPS2 filament assembly, suggesting a novel mode of regulation.

67 We solved cryoEM structures of substrate-bound (S-state) and product-bound (P-state)  
68 CTPS2 filaments. Initial reconstructions encompassing multiple tetramers revealed the helical  
69 architecture of the filaments (Fig. 1c, d), while masked refinements focused on single tetramers

70 produced higher resolution structures at 3.5Å and 3.1Å of the S-state and P-state filaments,  
71 respectively (Fig. 1e, f, Supplementary Fig. 1a-d, Supplementary Table 1). Both CTPS2  
72 filaments are composed of stacked tetramers, with a eukaryote-specific helical insert in the  
73 glutaminase domain forming the interfaces between tetramers. The filament assembly  
74 interactions are identical in both CTPS2 filament states (C $\alpha$  RMSD 0.8 Å), and are the same as  
75 the CTPS1 interface<sup>5</sup> (C $\alpha$  RMSD 1.3 Å) (Fig. 1g). We previously showed that mutation of  
76 conserved H355 at the filament interface completely abolishes CTPS1 polymerization<sup>5</sup>. This  
77 mutation has the same effect on both S- and P-state CTPS2 polymerization (Fig. 1b). However,  
78 CTPS1 filaments have additional interactions between poorly ordered C-terminal tails of  
79 adjacent tetramers<sup>5</sup>, which we did not observe in either CTPS2 filament (Supplementary Fig. 1i).

80 While the filament assembly interfaces are identical in both CTPS2 filament states, the  
81 conformation of the enzyme and the helical symmetry are strikingly different. The S-state  
82 CTPS2 and CTPS1 filaments are very similar at the level of monomer, tetramer, and filament<sup>5</sup>  
83 (Fig. 1c,e, Supplementary Fig. 1e-h). By contrast, tetramers in the CTPS2 P-state filament are  
84 in an inactive, CTP-inhibited conformation, similar to that observed in bacterial CTPS  
85 homologs<sup>5,10,14</sup> (Fig. 1d,f, Supplementary Fig. 1e-h). These differences in conformation result in  
86 different helical architectures. The two domains of each protomer rotate relative to each other by  
87 7° between the S- and P-states; the interactions at the interdomain interface remain fixed (C $\alpha$   
88 RMSD 0.8 Å), with the rotation arising from flexing of residues 40-87 relative to the core of the  
89 amidoligase domain (Supplementary Fig. 2a-d). The interdomain rotation alters the positions of  
90 filament contacts around the helical axis, leading to a 14° difference in the helical rotation per  
91 tetramer between the S-state and P-state filaments (Fig. 1c,d,h). Rare CTPS2 filaments  
92 observed in the absence of nucleotides had S-state architecture in negative stain  
93 reconstructions, suggesting this may be a somewhat more stable conformation of the enzyme  
94 (Supplementary Fig. 3). CTPS2 therefore assembles into active and inactive filaments with  
95 unique architectures, depending on the ligand-binding and conformational state of constituent  
96 tetramers, while maintaining a fixed filament interface.

97

### 98 **Novel product binding in the P-state CTPS2 filament**

99 The P-state CTPS2 filament structure revealed a novel ADP binding site. In all existing crystal  
100 and cryoEM structures of CTPS homologs with adenine nucleotides bound, the adenine ring  
101 binds to a pocket formed by R211 and the “lid” residues 238-244<sup>5,10</sup>. In S-state CTPS2 filaments  
102 ATP is bound in the same position as in previous structures. By contrast, in the P-state CTPS2  
103 filament, while the ADP phosphates are bound in the conventional position, the adenine base is

104 reoriented by approximately 90° towards the glutaminase domain, and packs in a new site  
105 between residues N73 and F77 (Fig. 2a-c). This suggests that the adenine base can bind both  
106 sites in CTPS2, and switches to the second site upon transition to the P-state. Furthermore, the  
107 overlap between the ATP and ADP binding sites could allow ADP to act as an allosteric  
108 regulator, similar to the allosteric regulation observed with CTP at the partially overlapping  
109 UTP/CTP binding site.

110 The CTP-binding mode in the P-state filament structure is the same as that in existing  
111 CTP-bound *E. coli* CTPS structures<sup>5,10</sup>: helix 224-234 is pulled towards CTP, with F233 packing  
112 against the CTP base, producing a hydrogen-bonding network amongst residues E161, R164,  
113 and H235 at the tetramerization interface (Fig. 2d, e). Consistent with this binding mode,  
114 mutation of these residues has been shown to eliminate feedback inhibition of CTPS<sup>1</sup>, including  
115 of CTPS1 in CHO cells that results in resistance to chemotherapeutic drugs<sup>7</sup>.

116

### 117 **Substrate binding opens a tunnel in the CTPS monomer**

118 The S-state CTPS2 filament structure is the first near-atomic resolution structure of any CTPS in  
119 the substrate-bound conformation, providing insight into the mechanism of ammonia transfer  
120 between the two active sites. Previous studies have identified a putative ~25 Å tunnel required  
121 to facilitate ammonia transfer between the glutaminase and amidoligase active sites<sup>14,24</sup> (Fig. 3).  
122 However, in the P-state CTPS2 structure as well as existing P-state bacterial structures, this  
123 tunnel is blocked by a constriction formed by conserved residues V58, P52, and H55 (V60, P54,  
124 and H57 in *E. coli*)<sup>14</sup> (Fig. 3a, c, Supplementary Fig. 4a, c). Based on a crystal structure of *E.*  
125 *coli* CTPS, Endrizzi *et al.*<sup>14</sup> predicted that H57 may act as a “gate” at the exit of the ammonia  
126 tunnel, with UTP binding altering the orientation of H57, causing the gate to open. Indeed, in the  
127 S-state CTPS2 filament, H55 reorients to interact with the UTP base, pulling loop P52-V58  
128 towards the amidoligase active site (Fig. 3b, d, Supplementary Fig. 4b, d) (Supplementary Video  
129 1). This conformational change opens the H55 gate and relieves the P52-V58 constriction,  
130 providing a tunnel with a nearly uniform ~4 Å diameter for ammonia transfer between the two  
131 active sites (Fig. 3e-h). This structural coupling of substrate binding with opening of the  
132 ammonia tunnel likely provides the mechanistic basis for the observed coupling of the two  
133 enzymatic activities of CTPS, which ensures ammonia is only released into the active site when  
134 a UTP substrate is present to accept it<sup>25</sup>.

135

136

137

### 138 **Regulation of CTPS2 filaments is highly cooperative**

139 Given that the filament interface is identical in the S-state and P-state structures, we  
140 hypothesized that CTPS2 filaments could directly switch between the S-state and P-states while  
141 remaining polymerized, perhaps allowing for coordinated conformational changes along entire  
142 filaments. To test this hypothesis, we trapped CTPS2 in filaments by engineering cysteine  
143 disulfide crosslinks at the filament interface, yielding the CTPS2<sup>CC</sup> mutant (Fig. 4a, b,  
144 Supplementary Fig. 5). In the absence of ligands CTPS2<sup>CC</sup> spontaneously and robustly  
145 polymerized into filaments under non-reducing conditions (Fig. 4c). We generated 2D averages  
146 of crosslinked CTPS2<sup>CC</sup> in different ligand states to probe for conformational changes within the  
147 filaments. Because their different helical symmetries give rise to a characteristic  $\sim 180^\circ$  repeated  
148 view every 300 Å (S-state) or 400 Å (P-state), the different architectures are readily  
149 distinguishable in 2D averages (Fig. 4d). Classification and alignment of 2D averages to low-  
150 pass filtered projections of the CTPS2 structures revealed that apo CTPS2<sup>CC</sup> filaments had S-  
151 state architecture and transitioned to the P-state upon addition of CTP, confirming that  
152 conformational switching within intact filaments is possible (Fig. 4e) (Supplementary Video 2).

153 We suspected that linking the conformational state of many CTPS2 subunits within a  
154 filament could lead to enhanced cooperativity in CTPS2 regulation. We therefore compared the  
155 UTP and CTP kinetic parameters of CTPS2 filaments with those of the CTPS2-H355A non-  
156 polymerizing mutant (Fig. 5, Supplementary Fig. 6). Unlike CTPS1<sup>5</sup>, polymerization did not  
157 increase the  $V_{\max}$  of CTPS2 (Fig. 5a). Further, CTPS2 filaments and CTPS2-H355A  
158 homotetramers exhibited nearly identical  $S_{0.5}$  and  $IC_{50}$  values for UTP and CTP (Fig. 5b-d,  
159 Supplementary Table 2). CTPS2-H355A inhibition is highly cooperative, with  $n_{\text{Hill}}$  of 3.5 that  
160 approaches the theoretical limit for a tetramer (Fig. 5c). CTPS kinetic parameters reported for  
161 various species vary significantly, but hill coefficients close to 4 have been reported for both  
162 activation and inhibition<sup>26,27</sup>. Remarkably, CTPS2 filaments exhibited an even higher  $n_{\text{Hill}}$  of 8.3,  
163 providing a switch-like response to changes in CTP concentrations (Fig. 5c). Dilution of wild-  
164 type CTPS2 below its critical concentration for assembly caused disassembly into tetramers and  
165 occasional short filaments, resulting in a  $n_{\text{Hill}}$  of 3.9, similar to that observed for the non-  
166 polymerizing mutant (Fig. 5d, f). Polymerization therefore greatly increases the cooperativity of  
167 CTPS2 regulation, likely due to concerted conformational changes within filaments (Fig. 5h).

168

169

170

171

172 **DISCUSSION**

173

174 Given that the residues involved in filament assembly interactions are completely conserved  
175 between CTPS1 and CTPS2, it is intriguing that CTPS1 forms S-state but not P-state filaments<sup>5</sup>.  
176 It is possible that product-bound CTPS1 adopts a unique conformation incompatible with  
177 filament assembly. Alternatively, the contact between disordered C-terminal regions observed in  
178 CTPS1<sup>5</sup> but not CTPS2 may play a role in differential assembly regulation; the C-terminus  
179 regulates CTPS2 activity in a phosphorylation-dependent manner and accounts for much of the  
180 sequence variation between isoforms<sup>28,29</sup>. Differences in the regulatory role of filaments  
181 between CTPS1 and CTPS2 may reflect their different physiological roles: consistent with its  
182 role in cellular proliferation during the immune response CTPS1 may be induced into filaments  
183 which reduce sensitivity to feedback inhibition and allow expansion of CTP pools to meet  
184 increased demand, whereas under more homeostatic conditions the extreme sensitivity of  
185 CTPS2 filaments may help maintain a strictly defined UTP/CTP balance.

186 Cooperativity in biological systems often arises from the association of protein subunits  
187 into oligomeric complexes, allowing for coordinated regulation through coupling of  
188 conformational states. Typically, cooperativity is associated with assemblies of relatively few  
189 protein subunits, with hemoglobin tetramers providing a canonical example. Large protein  
190 arrays and polymers hold the potential for massive cooperativity, with conformational  
191 information integrated across hundreds or thousands of protein subunits<sup>30-32</sup>. Several examples  
192 of this phenomenon occur in membrane-embedded systems where two-dimensional arrays can  
193 exhibit switchlike transitions, like the chemostatic network controlling bacterial flagellar motion  
194 where conformational states propagate across clusters of membrane-bound receptors to amplify  
195 external signals<sup>33-35</sup>, or the coupled gating of ryanodine receptor arrays in muscle cells<sup>36</sup>. In the  
196 case of CTPS2, highly cooperative enzyme regulation results from ligand-induced propagation  
197 of conformational changes along linear polymers. This allows for increased sensitivity to  
198 substrate and product balance. Sensitivity in the regulation of nucleotide biosynthesis is  
199 important to the maintenance of genomic integrity as imbalances in nucleotide pools are linked  
200 to increased mutagenesis, sensitization to DNA damaging agents, and multidrug resistance<sup>37,38</sup>.

201 Many enzymes in a broad range of metabolic pathways form filamentous polymers<sup>19,21,39-</sup>  
202 <sup>42</sup>. In the few examples that have been biochemically and structurally characterized to date,  
203 enzyme regulation arises from assembling filaments that stabilize particular conformational  
204 states<sup>1-5</sup>. The enhanced cooperativity of CTPS2 is a novel filament-based mechanism of  
205 enzyme regulation, which likely serves to stabilize nucleotide levels over a narrow concentration

206 range. This new function for metabolic filaments highlights the diversity of ways in which self-  
207 assembly can be adapted to allosterically fine-tune enzyme regulation and improve the  
208 efficiency of metabolic control.

209

## 210 **Acknowledgments**

211 We thank G. Carman (Rutgers University) for the hCTPS2-expressing *S. cerevisiae* strain. We  
212 are grateful to the Arnold and Mabel Beckman Cryo-EM Center at the University of Washington  
213 for use of electron microscopes.

214

## 215 **Funding**

216 This work was supported by the US National Institutes of Health (R01 GM118396 to J.M.K.).

217

## 218 **Data availability**

219 EM structures and atomic models have been deposited in the Electron Microscopy Data Bank  
220 and Protein Data Bank with the accession codes: S state CTPS2 filament (EMD-20354; PDB  
221 6PK4), P state CTPS2 filament (EMD-20355; PDB 6PK7).

222

## 223 **Author contributions**

224 E.M.L. performed the experiments. E.M.L. and J.M.K designed experiments, performed data  
225 analysis and interpretation, and wrote the manuscript.

226

## 227 **Competing financial interests**

228 The authors declare no competing financial interests.

229

230

## 231 **METHODS**

232

### 233 **Purification of CTPS2**

234 CTPS2 was expressed in *Saccharomyces cerevisiae* strain GHY56, as described by Han *et al*<sup>43</sup>.  
235 In GHY56, both endogenous *Saccharomyces cerevisiae* CTP synthase genes URA7 and URA8  
236 are deleted. This lethal deletion is rescued by plasmid pDO105-CTPS2, which directs  
237 expression of C-terminally His<sub>6</sub>-tagged CTPS2 from the ADH1 promoter. GHY56 cells were  
238 grown in 4X YPD at 30°C, harvested by centrifugation, frozen as droplets in liquid nitrogen, and  
239 then ground into powder while frozen. Cell powder (~20g) was resuspended in lysis buffer (50

240 mM Tris-HCl, 200 mM NaCl, 0.3M sucrose, 20 mM imidazole, pH 8.0), and centrifuged at  
241 14,000 RPM for 40 minutes at 4°C in a Thermo Scientific Fiberlite F14-14 × 50cy rotor. Clarified  
242 lysate was loaded onto a 5 mL HisTrap FF Crude column (GE) on an ÄKTA Start  
243 chromatography system (GE) pre-equilibrated in column buffer (20 mM Tris-HCl, 0.5M NaCl, 45  
244 mM imidazole, 10% glycerol, pH 7.9). The column was washed with 25 column volumes (CV) of  
245 column buffer, and CTPS2 was eluted with 5CV of elution buffer (20 mM Tris-HCl, 0.5M NaCl,  
246 250 mM imidazole, 10% glycerol, pH 7.9) as 1 mL fractions. Fractions containing CTPS2 were  
247 pooled and dialyzed into storage buffer (20 mM Tris-HCl, 0.5M NaCl, 10% glycerol, 7 mM β-  
248 mercaptoethanol, pH 7.9) using Snakeskin 3500 MWCO dialysis tubing (Thermo Scientific).  
249 Dialyzed CTPS2 was then concentration approximately 5-fold using a 3 kDa cut-off centrifugal  
250 filter unit (Millipore), flash-frozen in liquid nitrogen, and stored at -80°C. CTPS2 mutants were  
251 purified using the same methods.

252

### 253 **Cloning of mutants**

254 CTPS2-H355A and CTPS2<sup>CC</sup> mutants were generated using the Gibson assembly method<sup>44</sup>.  
255 PCR was used to amplify two separate fragments of the pDO105-CTPS2 plasmid backbone  
256 flanking the mutation site, which were then ligated together with ~60 base pair DNA fragments  
257 containing the desired H355A or V352C mutations. Mutations were confirmed by Sanger  
258 sequencing.

259

### 260 **Negative-stain electron microscopy**

261 Prior to imaging, CTPS2 in storage buffer was exchanged into imaging buffer (20 mM Tris-HCl,  
262 100 mM NaCl, 7 mM β-mercaptoethanol, pH 7.9) using a 7K MWCO Zeba Spin Desalting  
263 Column (Thermo Scientific). For imaging CTPS2<sup>CC</sup> disulfide crosslinked filaments, protein was  
264 exchanged into non-reducing buffer (20 mM Tris-HCl, 100 mM NaCl, pH 7.9). 100 mM DTT was  
265 added to depolymerize CTPS2<sup>CC</sup> filaments. CTPS2 was applied to glow-discharged carbon-  
266 coated grids, stained with 0.7% uranyl formate, and imaged on a Tecnai G2 Spirit (FEI co.)  
267 operating at 120 kV. Images were acquired at 67,000× magnification on a US4000 4k × 4k CCD  
268 camera (Gatan, Inc.).

269

### 270 **Negative-stain electron microscopy image processing and reconstructions**

271 3D reconstruction of Apo CTPS2 filaments was performed using iterative helical real space  
272 reconstruction (IHRSR)<sup>45,46</sup> in SPIDER, with hsearch\_lorentz<sup>47</sup> used to refine helical symmetry  
273 parameters, and with D2 point-group symmetry enforced. Cryo-EM structures of S-state or P-



274 state CTPS2 filaments low-pass filtered to 40Å were used as starting models. 2D class  
275 averages of CTPS2<sup>CC</sup> were generated by manually picking particles and performing 2D  
276 classification in Relion<sup>48</sup>. CTPS2<sup>CC</sup> class averages were aligned to 30Å low-pass filtered  
277 projections of the S-state and P-state cryoEM structures using e2classvsproj.py in EMAN2<sup>49</sup>.

278

### 279 **Cryo-electron microscopy**

280 Cryo-EM samples were prepared by applying CTPS2 to glow-discharged CFLAT 1.2/1.3 holey-  
281 carbon grids (Protochips Inc.), blotting with a Vitrobot (FEI co.), and plunging into liquid ethane.  
282 CTPS2 was exchanged into imaging buffer and incubated with nucleotides for 5 minutes at  
283 37°C before preparing cryo-EM samples. Conditions for the S-state filament structure were 7  
284 µM CTPS2, 2 mM UTP, 2 mM ATP, 0.2 mM GTP, and 10 mM MgCl<sub>2</sub>. Conditions for the P-state  
285 filament structure were 8 µM CTPS2, 2 mM CTP, 2 mM ADP, and 10 mM MgCl<sub>2</sub>. Data for  
286 preliminary 3D reconstructions was collected on a Tecnai G2 F20 (FEI co.) operating at 200 kV.  
287 Movies were acquired on a K-2 Summit Direct Detect camera in counting mode with a pixel size  
288 of 1.26 Å/pixel, collecting 36 frames with a total dose of 45 electrons/Å<sup>2</sup>, with a defocus range of  
289 -1.0 to -2.5 µm. Data for high-resolution structures was collected on a Titan Krios (FEI co.)  
290 equipped with a Quantum GIF energy filter (Gatan Inc.) operating in zero-loss mode with a 20 eV  
291 slit width. Movies were acquired on a K-2 Summit Direct Detect camera in super-resolution  
292 mode with a pixel size of 0.525 Å/pixel, collecting 50 frames with a total dose of 90 electrons/Å<sup>2</sup>.  
293 Movies were collected within a defocus range of -1.0 to -2.5 µm. EPU (FEI co.) and Legicon<sup>50</sup>  
294 software were used for automated data collection.

295

### 296 **Cryo-electron microscopy image processing and reconstructions**

297 Movie frame alignment and dose-weighting was performed using MotionCor2<sup>51</sup>, and CTF  
298 parameters were estimated using GCTF<sup>52</sup>. For data collected on the Tecnai G2 F20, particles  
299 were picked manually using Appion<sup>53</sup>. 3D reconstructions at ~8Å resolution were generated  
300 using IHRSR<sup>45,46</sup> in SPIDER, using cylinders as starting models and imposing D2 symmetry,  
301 with helical symmetry refined using hsearch\_lorentz<sup>47</sup>. For Titan Krios data, particles were  
302 initially picked manually from a subset of images, and used to generate 2D averages in Relion<sup>48</sup>.  
303 These initial 2D averages were used as templates for Relion automated picking from all images.  
304 2D classification in Relion was used to remove poorly aligning particle picks, and well-defined  
305 particles were then subject to Relion auto-refinement, using the SPIDER reconstructions low-  
306 pass filtered to 30Å as starting models. D2 symmetry was imposed during all 3D refinement.  
307 Parameters, particles, and structures from Relion auto-refine were exported to cisTEM<sup>54</sup>, where

308 multiple further rounds of 2D and 3D classification were performed. Final reconstructions of S-  
309 state and P-state CTPS2 filaments were generated in cisTEM, using automatic refinement,  
310 followed by manual refinement with CTF refinement implemented. Maps were sharpened in  
311 cisTEM using a b-factor of 50 Å<sup>2</sup>. Resolutions were estimated using the FSC<sub>0.143</sub> cutoff. Details  
312 of 3D reconstructions are summarized in Supplementary Table 1.

313

### 314 **Model building**

315 MODELLER<sup>55</sup> was used to generate an initial homology model of the full-length CTPS2  
316 monomer, using partial crystal structures of the CTPS2 glutaminase (PDB 2V4U) and  
317 amidoligase domains (PDB 2VO1) aligned to a crystal structure of the full-length *E. Coli* CTPS  
318 monomer (PDB 2AD5). The CTPS2 glutaminase, amidoligase, and linker domains were fit  
319 individually as rigid bodies into EM maps using Chimera. Structures were then refined using  
320 multiple cycles of real-space refinement in Phenix<sup>56</sup> and Coot<sup>57</sup>.

321

### 322 **Tunnel modelling**

323 CAVER Analyst<sup>58</sup> software was used to model tunnels through the CTPS2 atomic models. The  
324 same starting coordinates were used for the S-state and P-state filaments, at a site adjacent to  
325 the glutaminase domain catalytic cysteine 399. Probe radii of 0.5Å and 1.5Å were used for the P  
326 and S-state structures, respectively, and other tunnel computation parameters were set to  
327 default values. The use of a less restrictive, smaller probe radius for the inhibited state allowed  
328 us to define a continuous tunnel through the constriction points. Plots of tunnel diameter versus  
329 distance were also produced in CAVER Analyst.

330

### 331 **CTPS2 kinetics**

332 Kinetic parameters for CTPS2 and CTPS2-H355A were determined using the ADP-Glo assay  
333 (Promega), using similar conditions to those described by Sakamoto *et al*<sup>59</sup>. Assays were  
334 performed in 50 mM K-HEPES, 5 mM KCl, 0.01% tween 20, 0.01% BSA, 20 mM MgCl<sub>2</sub>, pH  
335 8.0. All steps of the assay were performed at room temperature in black, low volume 384 well  
336 plates (Corning). UTP kinetic assays were performed with 1500 nM CTPS2, 0-150 μM UTP, 500  
337 μM ATP, 5 μM GTP, and 500 μM Glutamine. CTP inhibition assays were performed with 300  
338 nM or 1500 nM CTPS2, 0-70 μM CTP, 100 μM UTP, 100 μM ATP, 5 μM GTP, and 100 μM  
339 Glutamine. The total volume of the CTPS2 assays was 6 μl, and reactions were ran for 60  
340 minutes (300 nM CTPS2) or 12 minutes (1500 nM CTPS2). CTPS2 reactions were terminated  
341 by addition of 6 μl ADP-Glo reagent and incubated for 1 hour, after which 12 μl of kinase

342 detection reagent was added. After one hour, luminescence was recorded using a Varioskan  
343 Lux (Thermo Scientific) microplate reader. Assays were performed in triplicate, and three  
344 luminescence readings were taken for each assay and averaged. Kinetics data were fit by 4  
345 parameter logistic regression, solving for maximum rate, minimum rate, hill number, and IC<sub>50</sub> or  
346 S<sub>0.5</sub>. Data were plotted as percent maximum rate, according to the formula: 100\*[(observed -  
347 minimum)/(maximum - minimum)].

348  
349

## 350 REFERENCES (includes supplementary references)

351

- 352 1 Barry, R. M. *et al.* Large-scale filament formation inhibits the activity of CTP synthetase.  
353 *eLife* **3**, e03638, doi:10.7554/eLife.03638 (2014).
- 354 2 Anthony, S. A. *et al.* Reconstituted IMPDH polymers accommodate both catalytically  
355 active and inactive conformations. *Molecular biology of the cell*, doi:10.1091/mbc.E17-  
356 04-0263 (2017).
- 357 3 Webb, B. A., Dosey, A. M., Wittmann, T., Kollman, J. M. & Barber, D. L. The glycolytic  
358 enzyme phosphofructokinase-1 assembles into filaments. *The Journal of cell biology*  
359 **216**, 2305-2313, doi:10.1083/jcb.201701084 (2017).
- 360 4 Hunkeler, M. *et al.* Structural basis for regulation of human acetyl-CoA carboxylase.  
361 *Nature* **558**, 470-474, doi:10.1038/s41586-018-0201-4 (2018).
- 362 5 Lynch, E. M. *et al.* Human CTP synthase filament structure reveals the active enzyme  
363 conformation. *Nature structural & molecular biology* **24**, 507-514,  
364 doi:10.1038/nsmb.3407 (2017).
- 365 6 Trudel, M., Van Genechten, T. & Meuth, M. Biochemical characterization of the hamster  
366 thy mutator gene and its revertants. *The Journal of biological chemistry* **259**, 2355-2359  
367 (1984).
- 368 7 Whelan, J., Phear, G., Yamauchi, M. & Meuth, M. Clustered base substitutions in CTP  
369 synthetase conferring drug resistance in Chinese hamster ovary cells. *Nat Genet* **3**, 317-  
370 322, doi:10.1038/ng0493-317 (1993).
- 371 8 Aronow, B., Watts, T., Lassetter, J., Washtien, W. & Ullman, B. Biochemical phenotype  
372 of 5-fluorouracil-resistant murine T-lymphoblasts with genetically altered CTP synthetase  
373 activity. *The Journal of biological chemistry* **259**, 9035-9043 (1984).
- 374 9 Carman, G. M. & Zeimet, G. M. Regulation of phospholipid biosynthesis in the yeast  
375 *Saccharomyces cerevisiae*. *The Journal of biological chemistry* **271**, 13293-13296,  
376 doi:10.1074/jbc.271.23.13293 (1996).

- 377 10 Endrizzi, J. A., Kim, H., Anderson, P. M. & Baldwin, E. P. Mechanisms of product  
378 feedback regulation and drug resistance in cytidine triphosphate synthetases from the  
379 structure of a CTP-inhibited complex. *Biochemistry* **44**, 13491-13499,  
380 doi:10.1021/bi051282o (2005).
- 381 11 Habrian, C. *et al.* Inhibition of Escherichia coli CTP Synthetase by NADH and Other  
382 Nicotinamides and Their Mutual Interactions with CTP and GTP. *Biochemistry* **55**, 5554-  
383 5565, doi:10.1021/acs.biochem.6b00383 (2016).
- 384 12 Goto, M., Omi, R., Nakagawa, N., Miyahara, I. & Hirotsu, K. Crystal structures of CTP  
385 synthetase reveal ATP, UTP, and glutamine binding sites. *Structure* **12**, 1413-1423,  
386 doi:10.1016/j.str.2004.05.013 (2004).
- 387 13 MacDonnell, J. E., Lunn, F. A. & Bearne, S. L. Inhibition of E. coli CTP synthase by the  
388 "positive" allosteric effector GTP. *Biochim Biophys Acta* **1699**, 213-220,  
389 doi:10.1016/j.bbapap.2004.03.002 (2004).
- 390 14 Endrizzi, J. A., Kim, H., Anderson, P. M. & Baldwin, E. P. Crystal structure of Escherichia  
391 coli cytidine triphosphate synthetase, a nucleotide-regulated glutamine  
392 amidotransferase/ATP-dependent amidoligase fusion protein and homologue of  
393 anticancer and antiparasitic drug targets. *Biochemistry* **43**, 6447-6463,  
394 doi:10.1021/bi0496945 (2004).
- 395 15 Martin, E. *et al.* CTP synthase 1 deficiency in humans reveals its central role in  
396 lymphocyte proliferation. *Nature* **510**, 288-292, doi:10.1038/nature13386 (2014).
- 397 16 Kucuk, Z. Y., Zhang, K., Filipovich, L. & Bleesing, J. J. CTP Synthase 1 Deficiency in  
398 Successfully Transplanted Siblings with Combined Immune Deficiency and Chronic  
399 Active EBV Infection. *Journal of clinical immunology* **36**, 750-753, doi:10.1007/s10875-  
400 016-0332-z (2016).
- 401 17 Williams, J. C., Kizaki, H., Weber, G. & Morris, H. P. Increased CTP synthetase activity  
402 in cancer cells. *Nature* **271**, 71-73 (1978).
- 403 18 Fan, H., Lu, S., Wang, S. & Zhang, S. Identification of critical genes associated with  
404 human osteosarcoma metastasis based on integrated gene expression profiling. *Mol*  
405 *Med Rep*, doi:10.3892/mmr.2019.10323 (2019).
- 406 19 Carcamo, W. C. *et al.* Induction of cytoplasmic rods and rings structures by inhibition of  
407 the CTP and GTP synthetic pathway in mammalian cells. *PloS one* **6**, e29690,  
408 doi:10.1371/journal.pone.0029690 (2011).
- 409 20 Stochlic, T. I. *et al.* Ack kinase regulates CTP synthase filaments during Drosophila  
410 oogenesis. *EMBO reports* **15**, 1184-1191, doi:10.15252/embr.201438688 (2014).

- 411 21 Petrovska, I. *et al.* Filament formation by metabolic enzymes is a specific adaptation to  
412 an advanced state of cellular starvation. *eLife*, doi:10.7554/eLife.02409 (2014).
- 413 22 Aughey, G. N. *et al.* Nucleotide synthesis is regulated by cytoophidium formation during  
414 neurodevelopment and adaptive metabolism. *Biology open* **3**, 1045-1056,  
415 doi:10.1242/bio.201410165 (2014).
- 416 23 Calise, S. J. *et al.* Glutamine deprivation initiates reversible assembly of mammalian  
417 rods and rings. *Cellular and molecular life sciences : CMLS* **71**, 2963-2973,  
418 doi:10.1007/s00018-014-1567-6 (2014).
- 419 24 McCluskey, G. D. & Bearne, S. L. "Pinching" the ammonia tunnel of CTP synthase  
420 unveils coordinated catalytic and allosteric-dependent control of ammonia passage.  
421 *Biochim Biophys Acta Gen Subj* **1862**, 2714-2727, doi:10.1016/j.bbagen.2018.08.008  
422 (2018).
- 423 25 Willemoes, M. & Sigurskjold, B. W. Steady-state kinetics of the glutaminase reaction of  
424 CTP synthase from *Lactococcus lactis*. The role of the allosteric activator GTP  
425 incoupling between glutamine hydrolysis and CTP synthesis. *Eur J Biochem* **269**, 4772-  
426 4779 (2002).
- 427 26 Kang, G. J. *et al.* Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP  
428 synthetase. *The Journal of biological chemistry* **264**, 713-718 (1989).
- 429 27 Long, C. W. & Pardee, A. B. Cytidine triphosphate synthetase of *Escherichia coli* B. I.  
430 Purification and kinetics. *The Journal of biological chemistry* **242**, 4715-4721 (1967).
- 431 28 Kassel, K. M., Au da, R., Higgins, M. J., Hines, M. & Graves, L. M. Regulation of human  
432 cytidine triphosphate synthetase 2 by phosphorylation. *The Journal of biological*  
433 *chemistry* **285**, 33727-33736, doi:10.1074/jbc.M110.178566 (2010).
- 434 29 Choi, M. G. & Carman, G. M. Phosphorylation of human CTP synthetase 1 by protein  
435 kinase A: identification of Thr455 as a major site of phosphorylation. *The Journal of*  
436 *biological chemistry* **282**, 5367-5377, doi:10.1074/jbc.M610993200 (2007).
- 437 30 Bray, D. & Duke, T. Conformational spread: the propagation of allosteric states in large  
438 multiprotein complexes. *Annu Rev Biophys Biomol Struct* **33**, 53-73,  
439 doi:10.1146/annurev.biophys.33.110502.132703 (2004).
- 440 31 Wyman, J. Possible allosteric effects in extended biological systems. *J Mol Biol* **39**, 523-  
441 538 (1969).
- 442 32 Changeux, J. P., Thiery, J., Tung, Y. & Kittel, C. On the cooperativity of biological  
443 membranes. *Proceedings of the National Academy of Sciences of the United States of*  
444 *America* **57**, 335-341, doi:10.1073/pnas.57.2.335 (1967).

- 445 33 Sourjik, V. & Berg, H. C. Functional interactions between receptors in bacterial  
446 chemotaxis. *Nature* **428**, 437-441, doi:10.1038/nature02406 (2004).
- 447 34 Bai, F. *et al.* Conformational spread as a mechanism for cooperativity in the bacterial  
448 flagellar switch. *Science* **327**, 685-689, doi:10.1126/science.1182105 (2010).
- 449 35 Cluzel, P., Surette, M. & Leibler, S. An ultrasensitive bacterial motor revealed by  
450 monitoring signaling proteins in single cells. *Science* **287**, 1652-1655 (2000).
- 451 36 Marx, S. O., Ondrias, K. & Marks, A. R. Coupled gating between individual skeletal  
452 muscle Ca<sup>2+</sup> release channels (ryanodine receptors). *Science* **281**, 818-821 (1998).
- 453 37 Meuth, M. The molecular basis of mutations induced by deoxyribonucleoside  
454 triphosphate pool imbalances in mammalian cells. *Exp Cell Res* **181**, 305-316 (1989).
- 455 38 Mathews, C. K. Deoxyribonucleotide metabolism, mutagenesis and cancer. *Nat Rev*  
456 *Cancer* **15**, 528-539, doi:10.1038/nrc3981 (2015).
- 457 39 Noree, C., Sato, B. K., Broyer, R. M. & Wilhelm, J. E. Identification of novel filament-  
458 forming proteins in *Saccharomyces cerevisiae* and *Drosophila melanogaster*. *The*  
459 *Journal of cell biology* **190**, 541-551, doi:10.1083/jcb.201003001 (2010).
- 460 40 Liu, J. L. Intracellular compartmentation of CTP synthase in *Drosophila*. *Journal of*  
461 *genetics and genomics = Yi chuan xue bao* **37**, 281-296, doi:10.1016/S1673-  
462 8527(09)60046-1 (2010).
- 463 41 Ingerson-Mahar, M., Briegel, A., Werner, J. N., Jensen, G. J. & Gitai, Z. The metabolic  
464 enzyme CTP synthase forms cytoskeletal filaments. *Nature cell biology* **12**, 739-746,  
465 doi:10.1038/ncb2087 (2010).
- 466 42 Shen, Q. J. *et al.* Filamentation of Metabolic Enzymes in *Saccharomyces cerevisiae*.  
467 *Journal of genetics and genomics = Yi chuan xue bao* **43**, 393-404,  
468 doi:10.1016/j.jgg.2016.03.008 (2016).
- 469 43 Han, G. S. *et al.* Expression of Human CTP synthetase in *Saccharomyces cerevisiae*  
470 reveals phosphorylation by protein kinase A. *The Journal of biological chemistry* **280**,  
471 38328-38336, doi:10.1074/jbc.M509622200 (2005).
- 472 44 Gibson, D. G. *et al.* Enzymatic assembly of DNA molecules up to several hundred  
473 kilobases. *Nature methods* **6**, 343-345, doi:10.1038/nmeth.1318 (2009).
- 474 45 Egelman, E. H. The iterative helical real space reconstruction method: surmounting the  
475 problems posed by real polymers. *Journal of structural biology* **157**, 83-94,  
476 doi:10.1016/j.jsb.2006.05.015 (2007).
- 477 46 Sachse, C. *et al.* High-resolution electron microscopy of helical specimens: a fresh look  
478 at tobacco mosaic virus. *J Mol Biol* **371**, 812-835, doi:10.1016/j.jmb.2007.05.088 (2007).

- 479 47 Egelman, E. H. A robust algorithm for the reconstruction of helical filaments using single-  
480 particle methods. *Ultramicroscopy* **85**, 225-234 (2000).
- 481 48 Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure  
482 determination. *Journal of structural biology* **180**, 519-530, doi:10.1016/j.jsb.2012.09.006  
483 (2012).
- 484 49 Tang, G. *et al.* EMAN2: an extensible image processing suite for electron microscopy.  
485 *Journal of structural biology* **157**, 38-46, doi:10.1016/j.jsb.2006.05.009 (2007).
- 486 50 Suloway, C. *et al.* Automated molecular microscopy: the new Legion system. *Journal of*  
487 *structural biology* **151**, 41-60, doi:10.1016/j.jsb.2005.03.010 (2005).
- 488 51 Zheng, S. Q. *et al.* MotionCor2: anisotropic correction of beam-induced motion for  
489 improved cryo-electron microscopy. *Nature methods* **14**, 331-332,  
490 doi:10.1038/nmeth.4193 (2017).
- 491 52 Zhang, K. Gctf: Real-time CTF determination and correction. *Journal of structural biology*  
492 **193**, 1-12, doi:10.1016/j.jsb.2015.11.003 (2016).
- 493 53 Lander, G. C. *et al.* Appion: an integrated, database-driven pipeline to facilitate EM  
494 image processing. *Journal of structural biology* **166**, 95-102 (2009).
- 495 54 Grant, T., Rohou, A. & Grigorieff, N. cisTEM, user-friendly software for single-particle  
496 image processing. *eLife* **7**, doi:10.7554/eLife.35383 (2018).
- 497 55 Webb, B. & Sali, A. Comparative Protein Structure Modeling Using MODELLER. *Curr*  
498 *Protoc Protein Sci* **86**, 2 9 1-2 9 37, doi:10.1002/cpps.20 (2016).
- 499 56 Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for macromolecular  
500 structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-221,  
501 doi:10.1107/S0907444909052925 (2010).
- 502 57 Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot.  
503 *Acta Crystallogr D Biol Crystallogr* **66**, 486-501, doi:10.1107/S0907444910007493  
504 (2010).
- 505 58 Jurcik, A. *et al.* CAVER Analyst 2.0: analysis and visualization of channels and tunnels in  
506 protein structures and molecular dynamics trajectories. *Bioinformatics* **34**, 3586-3588,  
507 doi:10.1093/bioinformatics/bty386 (2018).
- 508 59 Sakamoto, K. *et al.* Identification of cytidine-5-triphosphate synthase1-selective inhibitory  
509 peptide from random peptide library displayed on T7 phage. *Peptides* **94**, 56-63,  
510 doi:10.1016/j.peptides.2017.06.007 (2017).
- 511
- 512

## 513 Figures

514

### 515 Video legends:

516 **Supplementary Video 1:** Animation of the CTPS2 active site morphing between the S-state  
517 and P-state conformations. The glutaminase domain (green) rotates towards the amidoligase  
518 domain (blue), while loop P52-V58 (orange) is pulled towards the UTP base (magenta) in the S-  
519 state. ATP (yellow) is also shown in the active site.


520

521 **Supplementary Video 2:** Animation of CTPS2 morphing between the S-state and P-state  
522 filament conformations. Colored by tetramer. Filament contact sites (orange) remain the same  
523 despite conformation changes between the two filament states.

524

525

526




527

528

529 **Fig. 1: CTPS2 forms distinct S and P-state filaments using the same filament interface.**

530 (a,b) Negative stain EM images of CTPS2 wild-type (a) or CTPS2-H355A non-polymerizing  
531 mutant (b) in the presence of substrates or products. (c,d) Initial cryoEM reconstructions of S-  
532 state (c) (4Å resolution) and P-state (d) (3.6 Å resolution) CTPS2 filaments showing differing  
533 helical symmetry, colored by tetramer. Helical rise and rotation are indicated. (e,f) High-  
534 resolution reconstructions of S-state (e) (3.5Å resolution) and P-state (f) (3.1 Å resolution)  
535 CTPS2 filaments focused on a single tetramer, colored by protomer. Nucleotides are colored as  
536 indicated. (g) The filament interface (orange box in c,d) is identical in the CTPS2 S-state (color),  
537 CTPS2 P-state (dark grey), and CTPS1 S-state (light grey) structures. Position of conserved  
538 H355 is indicated. (h) View down the helical axis comparing the positions of the filament  
539 contacts (orange box) in the S-state (color) and P-state (grey) filaments.






540

541

542

543 **Supplementary Fig. 1: Details of CTPS2 cryoEM structures.** (a,b) FSC curves for the S-state  
544 (a) and P-state (b) CTPS2 filament structures, showing resolutions of 3.5Å and 3.1Å,  
545 respectively, by the FSC<sub>0.143</sub> criteria. (c,d) ResMap local resolution maps of the S-state (c) and  
546 P-state (d) CTPS2 filament structures. (e) CTPS2 tetramer, with monomers A-D shown in  
547 different colors. (f) Zoomed-in view of the orange box in (e), showing S-state CTPS2 (blue), P-  
548 state CTPS2 (dark grey), and S-state CTPS1 (light grey) filament structures aligned on the  
549 Amidoligase domain of subunit A. S-state CTPS1 and CTPS2 are extended across the tetramer  
550 interface, compared to P-state CTPS2. (g) Monomers from the S-state (green) and P-state (dark  
551 grey) CTPS2 filament structures aligned on the Amidoligase domain. (h) Zoomed-in view of the  
552 blue box in (g), with S-State CTPS1 also shown in light grey. The glutaminase domain is rotated  
553 by 7° towards the Amidoligase domain in the S-state structure. (i) CryoEM maps of CTPS1 and  
554 CTPS2 filaments, low-pass filtered to 8Å for comparison. CTPS1 filaments have an additional,  
555 poorly ordered, C-terminal filament contact (orange) that is not observed in S- or P-state CTPS2  
556 filaments.

557



558

559

560 **Supplementary Fig. 2: Comparison of the Glutaminase-Amidoligase interface in S- and P-**

561 **state CTPS2 filaments.** (a,b) Two views of the S-state (color) and P-state (grey) CTPS2


562 monomers aligned on the glutaminase-amidoligase interface. (c) Zoomed-in view of the yellow

563 box in (a). (d) Zoomed-in view of the orange box in (b). The glutaminase-amidoligase interface

564 is essentially identical (C $\alpha$  RMSD 0.8 Å) in the S-state and P-state filaments.

565

566



567

568

569 **Supplementary Fig. 3: Rare apo CTPS2 filaments have S-state filament architecture.** (a)

570 Negative stain EM images of apo CTPS2. Occasional filaments are observed. (b) Helical rise

571 (red) and rotation (black) values plotted over multiple rounds of iterative helical real space

572 reconstruction of apo CTPS2 filaments in stain. Starting helical symmetry values and models

573 from cryoEM structures of S-state (closed circles) or P-state (open circles) CTPS2 filaments

574 were used. Both reconstructions converge on the S-state filament helical symmetry values. (c)

575 The apo CTPS2 filament structures from the reconstructions described in (b) are the same and

576 have the S-state helical rotation, regardless of which starting symmetries and models are used.

577

578


579

580

581

582


583



584  
585


586 **Fig. 2: Product binding and changes in the tetramer interface in CTPS2 structures.** (a)  
587 CTPS2 P-state tetramer, colored by monomer. (b) Zoomed-in view of the yellow box in (a),  
588 showing ADP (orange) bound in a novel conformation. cryoEM density is shown in transparent  
589 grey. (c) Comparison of ADP conformations in the CTPS2 P-state filament (color) with existing  
590 ADP-bound CTPS structures (grey). ADP in the P-state filament is packed between residues  
591 F77 and N73. In other CTPS structures, ADP is bound to a pocket formed by R217 and lid  
592 residues 244-250 (dashed blue box). (d) Zoomed-in view of the black box in (a), showing the  
593 CTP binding site. (e) Comparison of the tetramer interface around the CTP binding site in the P-  
594 state (blue and green) and S-state (grey) structures.

595  
596  
597  
598  
599  
600  
601  
602  
603




604  
605

606 **Fig. 3: UTP binding opens a tunnel connecting the amidoligase and glutaminase active**  
 607 **sites in the S-state CTPS2 filament.** (a,b) Conformation of residues at the P52-V58  
 608 constriction in the P-state (a) and S-state (b) CTPS2 filaments. (c,d) Position of the H55 gate in  
 609 the P-state (c) and S-state (d) CTPS2 filaments. (e) CTPS2 monomer showing the position of  
 610 the tunnel (blue) linking the Glutaminase (light grey) and Amidoligase (dark grey) domains. (f,g)  
 611 Zoomed-in view of the yellow box in (e), showing tunnels identified by CAVER software in the P-  
 612 state (f) and S-state (g) CTPS2 structures. Positions of the H55 gate (blue arrow) and P52-V58  
 613 constriction (orange arrow) in the P-state structure are indicated. The expected position of  
 614 glutamine is shown in purple (based on PDB 1VCO). (h) Plot showing the diameter of the tunnel  
 615 along its length for P and S-state structures, with positions of the H55 gate (blue arrow) and  
 616 P52-V58 constriction (orange arrow) indicated.




617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634

**Supplementary Fig. 4: CryoEM density at the P52-V58 and H55 constriction points.** (a,b) CryoEM density (grey) and atomic models (color) at the H55 gate in the P-state (a) and S-state (b) CTPS2 filaments. (c,d) CryoEM density (grey) and atomic models (color) at the P52-V58 constriction in the P-state (c) and S-state (d) CTPS2 filaments.




635  
 636 **Fig. 4: Disulfide-crosslinked CTPS2 filaments can switch conformations.** (a) CTPS2  
 637 filament showing the position of the CTPS2<sup>CC</sup> mutant at the filament interface. (b) Zoomed-in  
 638 view of the orange box in (a), showing the design of the CTPS2<sup>CC</sup> mutant. The V352C mutation  
 639 is across from native C362. (c) Negative stain EM images of hCTPS<sup>CC</sup> under reducing  
 640 conditions (+DTT), and under non-reducing conditions in the presence or absence of  
 641 nucleotides. (d) 2D averages of S and P-state CTPS2<sup>CC</sup> filaments, with characteristic 180°  
 642 repeat distances indicated. (e) 2D class averages of cross-linked CTPS2<sup>CC</sup> filaments before and  
 643 after addition of CTP. 2D averages (A) are aligned to low-pass filtered projections of CTPS2  
 644 cryoEM models (M) in the S-state (top) and P-state (bottom) conformations.  
 645




646  
 647 **Supplementary Fig. 5: SDS-PAGE gel of wild-type CTPS2 and CTPS2<sup>CC</sup> under reducing (100**  
 648 **mM DTT) and non-reducing conditions. Bands for crosslinked CTPS2<sup>CC</sup> are visible under non-**  
 649 **reducing conditions.**  
 650

651  
 652



653  
 654 **Fig. 5: Regulation of CTPS2 filaments is highly cooperative.** (a-d) ADP-Glo enzyme assays  
 655 comparing kinetics of CTPS2 filaments and tetramers. (a)  $V_{max}$  is the same for CTPS2 filaments  
 656 and CTPS2-H355A tetramers. (b) UTP kinetic curves for CTPS2 and CTPS2-H355A. Assays  
 657 were performed with 1500 nM enzyme. (c) CTP inhibition curves for CTPS2 and CTPS2-H355A  
 658 at 1500 nM protein.  $n_{Hill}$  values are indicated. (d) CTP inhibition curve for CTPS2 at 300 nM  
 659 protein. Fits for CTPS2 and CTPS2-H355A inhibition from panel (c) are reproduced for  
 660 comparison.  $n_{Hill}$  value is indicated. (e-g) Negative stain EM images of CTPS2 and CTPS2-  
 661 H355A under ADP-Glo assay conditions. CTPS2 forms filaments at 1500 nM concentration (e),  
 662 but disassembles into tetramers and rare short filaments at 300 nM concentration (f). CTPS2-  
 663 H355A does not form filaments at 1500 nM concentration (g). (h) Model for cooperative  
 664 regulation in hCTPS2 filaments. CTP-binding induces conformational changes which propagate  
 665 along filaments. Assays were performed in triplicate (6 assays for CTPS2 in (c)) and measured  
 666 in triplicate, and values are presented as mean  $\pm$  s.d.

667  
 668  
 669  
 670  
 671  
 672  
 673



674  
 675 **Supplementary Fig. 6:** ADP-Glo assays show a linear response in relative light units (RLU)  
 676 over the time used for CTPS2 kinetics assays. (a) Time-course of ADP-Glo assay under the  
 677 substrate conditions used for CTP inhibition assays at 300 nM CTPS2 (open circles) and 1500  
 678 nM CTPS2 (closed circles). (b) Time-course of ADP-Glo assay at 1500 nM CTPS2 with the  
 679 lowest UTP concentration used in UTP kinetics assays (10  $\mu$ M UTP). Dashed lines indicate the  
 680 linear portion of the assay used to measure reaction velocity. Assays were performed in  
 681 triplicate and measured in triplicate, and values are presented as mean +/- s.d.

682

683

684

### Supplementary Table 1: EM data collection and refinement statistics

	<b>S state CTPS2 filament</b> (EMD-20354, PDB 6PK4)	<b>P state CTPS2 filament</b> (EMD-20355, PDB 6PK7)
<b>Data collection</b>		
Electron microscope	Titan Krios	Titan Krios
Voltage (kV)	300	300
Electron detector	K2 summit	K2 summit
Electron dose ( $e^-/\text{\AA}^2$ )	90	90
Pixel size ( $\text{\AA}$ )	1.05	1.05
<b>Reconstruction</b>		
Point group symmetry	D2	D2
Helical symmetry (rise, rotation)	101.5 $\text{\AA}$ , 55.3 $^\circ$	101.5 $\text{\AA}$ , 41.7 $^\circ$
Particles	53964	22705
Resolution (0.143 fsc) ( $\text{\AA}$ )	3.5	3.1
<b>Refinement</b>		
Initial model used	PDB 2V4U, PDB 2VO1	PDB 2V4U, PDB 2VO1
<b>Model composition</b>		
Protein residues	559	557
Ligands	UTP, ATP, Mg	CTP, ADP, Mg
<b>Validation</b>		
Clashscore	12	11
Poor rotamers (%)	1	0.4
<b>Ramachandran plot</b>		
Favored (%)	92	91
Allowed (%)	8	9
Outliers (%)	1	0



685 **Supplementary Table 2: Summary of CTPS2 kinetic parameters**

	UTP kinetics		CTP inhibition	
	S <sub>0.5</sub> (μM)	n <sub>Hill</sub>	IC <sub>50</sub> (μM)	n <sub>Hill</sub>
CTPS2 (1500 nM)	11.7	2.8	21.0	8.3
CTPS2-H355A (1500 nM)	14.0	1.1	17.1	3.5
CTPS2 (300 nM)	-	-	19.2	3.9

686